Expert Interviews

Derm Dispatch host Renata Block, DMSc, MMS, PA-C, and Obehi Oriaifo, DNP, FNP-BC, DCNP, founder of DermaNP Solutions, discuss barriers driving demand for teledermatology in rural and underserved communities.

In this segment, Dr. Tina Bhutani-Jacques expands on the rationale for selecting roflumilast 0.3% foam for a patient with plaque psoriasis affecting both the scalp and body.

Shawn Demehri, MD, PhD, discussed a topical combination immunotherapy being studied for skin cancer prevention in high-risk patients.

Stephanie Kauffman, chief executive officer of the Melanoma Research Alliance, discussed funding strategy, early career researcher support, and melanoma prevention in a recent Dermatology Times interview.

Twelve years of inconsistent care have left this patient reluctant to even be in the room. The panel sets short- and long-term goals for HS.

Choosing between TNF and IL-17 inhibition is only part of the picture. The panel maps out comorbidity screening, pain management, and where cannabis fits in.

Daniel Butler, MD, discusses the 5Ms of geriatric care, shared decision-making, deprescribing, and emerging approaches to chronic itch.

Lisa Weiss, PA-C, discussed why continuous learning and conference attendance remain valuable for dermatology PAs at every career stage.

"Reading the Risankizumab Claims Data: Protopathic Bias and Study Limitations" weighs what the data can and cannot support.

Heather Woolery-Lloyd, MD, discusses how new linear hair growth rate data translates into real-world results for patients.

Victoria Garcia-Albea, NP, discussed the learning curve for dermatology NP fellows and how continued education parallels the evolution of the specialty.

Eileen Cheever, PA, shared how mentorship, experienced colleagues, and conference attendance can support professional growth and patient care.

Heather Woolery-Lloyd, MD, reviews a new clinical study quantifying linear hair growth rate across 4 Nutrafol formulations.

In this episode, Dr. Tina Bhutani-Jacques presents the second case, featuring a 45-year-old woman with plaque psoriasis affecting both the scalp and body.

In this segment, Dr. Tina Bhutani-Jacques discusses the clinical rationale for transitioning patients with plaque psoriasis to newer nonsteroidal topical therapies when previous treatments have provided inadequate efficacy or tolerability.

In the new episode of Don't Be Rash, learn why early pulsed dye laser helps pediatric PWCMs, what drives recurrence, and which new therapies may boost results.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

Alexandra Richmond, MD, explains realistic hair-loss timelines, scarring alopecia limits, combination therapies, PRP and supplements, plus promising insights on extended‑release oral minoxidil.

This patient hasn't reached Hurley Stage 3, but her quality of life already has. The panel makes the case for escalating therapy well before anatomic damage sets in.

A five-year history of 'ingrown hairs' turns out to be HS. The panel explores why primary care so often misses this diagnosis, and how to rebuild trust once it's finally named.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Dr. Chandra details the CPOST trial, a randomized phase 3 study in which 415 patients received either adjuvant cemiplimab for one year or placebo.

This episode, "Inside the Risankizumab and PsA Risk Study: Claims Data on Targeted Immunomodulator Therapies," examines the study design and the numbers behind it.

Learn how dermatologists can pinpoint causes of scarring vs nonscarring hair loss, avoid biotin pitfalls, and choose personalized treatments early.

A 48-year-old man with chronic plaque psoriasis develops new intertriginous involvement unresponsive to prior topical regimens. Dr. Bhutani-Jacques outlines how lesion location and treatment history inform selection of a non-steroidal topical agent.

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Aaron Farberg, MD, outlines common triggers of generalized pustular psoriasis flares and the role of IL-36 targeted therapy.

Aaron Farberg, MD, reviews the diagnostic challenges of generalized pustular psoriasis and its common mimics across care settings.